Faron Pharmaceuticals
0.62 EUR
+3.33 %
5,661 following
Corporate customer
FARON
First North Finland
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Dividend
Investor consensus
+3.33 %
-66.38 %
-70.19 %
-69.90 %
-72.87 %
-69.83 %
-83.40 %
-83.51 %
-82.18 %
Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.
Read moreMarket cap
74.07M EUR
Turnover
463.24K EUR
P/E (adj.) (26e)
-5.91
EV/EBIT (adj.) (26e)
-6.51
P/B (26e)
20.96
EV/S (26e)
30,937.32
Dividend yield-% (26e)
-
Revenue and EBIT-%
Revenue K
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
30.3
2026
General meeting '26
26.8
2026
Interim report Q2'26
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types
DNB Carnegie Access: Faron Pharmaceuticals: Financing terms remain in focus – H2 review
Faron H2'25: High stakes in financing success
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
